| Literature DB >> 29880779 |
Zachary C Pope1, Nan Zeng2, Rui Zhang3,4, Hee Yun Lee5, Zan Gao6.
Abstract
Physical activity (PA) among breast cancer survivors (BCS) can improve this population's health and quality of life (QoL). This study evaluated the effectiveness of a combined smartwatch- and social media-based health education intervention on BCS's health outcomes. Thirty BCS ( X ¯ age = 52.6 ± 9.3 years; X ¯ Wt = 80.2 ± 19.6 kg) participated in this 10-week, 2-arm randomized trial, with BCS randomized into: (1) experimental group (n = 16): received Polar M400 smartwatches for daily PA tracking and joined a Facebook group wherein Social Cognitive Theory-related PA tips were provided twice weekly; and (2) comparison group (n = 14): only joined separate, but content-identical Facebook group. Outcomes included PA, physiological, psychosocial, and QoL variables. Specifically, PA and energy expenditure (EE) was assessed by ActiGraph GT3X+ accelerometers while physiological, psychosocial, and QoL were examined via validated instruments at baseline and post-intervention. No baseline group differences were observed for any variable. Ten BCS dropped out of the study (experimental: 4; comparison: 6). Compared to completers, dropouts differed significantly on several outcomes. Thus, a per-protocol analysis was performed, revealing significant group differences for changes in social support (t = -2.1, p = 0.05) and barriers (t = -2.2, p = 0.04). Interestingly, the comparison group demonstrated improvements for both variables while the intervention group demonstrated slightly decreased social support and no change in barriers. Notably, both groups demonstrated similarly increased daily light PA, moderate-to-vigorous PA, EE, and steps of 7.7 min, 5.1 min, 25.1 kcals, and 339 steps, respectively, over time. Despite extensive user training, several experimental BCS found the Polar M400 use difficult-possibly decreasing intervention adherence. Future interventions should utilize simpler smartwatches to promote PA among middle-aged clinical/non-clinical populations.Entities:
Keywords: physical activity; quality of life; social cognitive theory; wearable technology
Year: 2018 PMID: 29880779 PMCID: PMC6025572 DOI: 10.3390/jcm7060140
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1CONSORT study participant flow diagram.
Participant baseline comparisons for clinical and demographic characteristics *.
| Demographic Characteristics ( | |||||
|---|---|---|---|---|---|
| Experimental ( | Comparison ( | ||||
| Avg. ( | Freq. (Counts) | Avg. ( | Freq. (Counts) | ||
| Age (years) | 50.6 ± 7.4 | 54.9 ± 11.0 | 0.23 | ||
| Race/ethnicity | 0.28 | ||||
| ● Caucasian | 16 | 13 | |||
| ● Hispanic | 0 | 1 | |||
| Educational status | 0.98 | ||||
| ● Some college/technical school | 2 | 2 | |||
| ● College graduate | 5 | 4 | |||
| ● Graduate school | 9 | 8 | |||
| Health insurance | 0.12 | ||||
| ● Private | 16 | 12 | |||
| ● Medicaid | 0 | 2 | |||
| Employment status | 0.46 | ||||
| ● Full time | 9 | 7 | |||
| ● Part time | 5 | 4 | |||
| ● Retired | 0 | 2 | |||
| ● Housewife | 2 | 1 | |||
| Marital status | 0.60 | ||||
| ● Married | 14 | 10 | |||
| ● Separated/divorced | 1 | 2 | |||
| ● Widowed | 0 | 1 | |||
| ● Living with unmarried partner | 1 | 1 | |||
| Annual income (USD) | 0.65 | ||||
| ● $10,001–20,000 | 1 | 1 | |||
| ● $30,001–40,000 | 1 | 2 | |||
| ● $40,001–50,000 | 0 | 1 | |||
| ● $50,000–74,999 | 0 | 1 | |||
| ● $75,000–99,999 | 4 | 3 | |||
| ● ≥$100,000 | 10 | 6 | |||
|
| |||||
| Time in remission | 60.7 ± 39.7 | 48.7 ± 31.7 | 0.37 | ||
| Months since diagnosis | 0.12 | ||||
| ● ≤12 months | 0 | 1 | |||
| ● 13 to 24 months | 5 | 1 | |||
| ● 25 to 36 months | 2 | 3 | |||
| ● 49 to 60 months | 0 | 3 | |||
| ● ≥61 months | 9 | 6 | |||
| Diagnosed breast cancer stage | 0.68 | ||||
| ● Stage 0 | 3 | 1 | |||
| ● Stage 1 | 4 | 5 | |||
| ● Stage 2 | 7 | 5 | |||
| ● Stage 3 | 2 | 3 | |||
| Treatment type | 0.64 | ||||
| ● Surgery only | 2 | 4 | |||
| ● Surgery + radiation | 2 | 1 | |||
| ● Surgery + chemo | 5 | 5 | |||
| ● Surgery + radiation + chemo | 7 | 4 | |||
| Tamoxifen use | 0.92 | ||||
| ● Yes | 10 | 9 | |||
| ● No | 6 | 5 | |||
| Follow-up care in past 12 months | 1.00 | ||||
| ● Yes | 16 | 14 | |||
| ● No | 0 | 0 | |||
| Clinical breast exam frequency | 0.57 | ||||
| ● Never | 1 | 0 | |||
| ● Every 3–6 months | 2 | 2 | |||
| ● Every 6–12 months | 5 | 5 | |||
| ● Once yearly | 6 | 7 | |||
| ● Other | 2 | 0 | |||
| Comorbidities | 0.23 | ||||
| ● None | 13 | 14 | |||
| ● 1 | 1 | 0 | |||
| ● ≥2 | 2 | 0 | |||
* Intent-to-treat analysis presented. Avg. = average; M = Mean; SD = Standard Deviation; Freq. = Frequency.
Baseline comparisons for participants’ primary and secondary outcomes *,a.
| Experimental ( | Comparison ( | ||
|---|---|---|---|
| Primary Outcomes | |||
| Daily MVPA | 26.7 ± 18.4 | 20.9 ± 17.6 | 0.40 |
| Daily LPA | 72.9 ± 44.1 | 77.3 ± 48.2 | 0.80 |
| Daily SB | 378.0 ± 192.5 | 361.7 ± 201.0 | 0.82 |
| Daily EE | 272.5 ± 166.6 | 303.1 ± 240.9 | 0.69 |
| Daily steps | 4099.8 ± 2651.6 | 3092.7 ± 2214.0 | 0.27 |
|
| |||
| Physiological variables | |||
| Weight (kg) | 76.0 ± 13.0 | 85.0 ± 24.9 | 0.24 |
| Body fat (%) | 39.4 ± 5.5 | 38.6 ± 9.8 | 0.81 |
| Cardiorespiratory fitness | 113.2 ± 20.7 | 106.1 ± 23.4 | 0.39 |
| Psychosocial variables | |||
| Self-efficacy # | 73.3 ± 22.1 | 80.3 ± 14.5 | 0.33 |
| Social support $ | 2.8 ± 1.1 | 2.1 ± 1.0 | 0.06 |
| Enjoyment $ | 3.2 ± 0.5 | 3.3 ± 0.5 | 0.55 |
| Barriers @ | 2.0 ± 0.5 | 1.9 ± 0.4 | 0.57 |
| Outcome expectancy $ | 3.9 ± 0.5 | 4.1 ± 0.5 | 0.55 |
| Quality of life variables | |||
| Physical functioning ** | 1.2 ± 0.4 | 1.3 ± 0.3 | 0.64 |
| Anxiety ** | 1.8 ± 0.8 | 1.5 ± 0.7 | 0.34 |
| Depression ** | 1.3 ± 0.3 | 1.1 ± 0.3 | 0.21 |
| Fatigue ** | 2.5 ± 1.1 | 2.3 ± 0.6 | 0.51 |
| Sleep quality ** | 3.1 ± 1.0 | 3.4 ± 0.9 | 0.39 |
| Sleep disturbances ** | 2.9 ± 0.6 | 2.6 ± 0.5 | 0.17 |
| Social roles/activities limitations ** | 2.2 ± 1.1 | 2.1 ± 0.8 | 0.76 |
| Pain limitations ** | 1.7 ± 0.8 | 1.5 ± 0.6 | 0.51 |
| Pain intensity & | 2.0 ± 1.3 | 2.2 ± 1.9 | 0.72 |
* All values Mean ± Standard Deviation; a Intent-to-treat analysis presented; # Evaluated on a percentage confidence scale from 0% (Not confident at all) to 100% (Extremely confident); $ Evaluated on 5-point Likert-type scale; @ Evaluated on 4-point Likert-type scale; ** Evaluated on a 5-point Likert-type scale; & Evaluated on a scale from 0 (no pain) to 10 (worst pain imaginable).
Descriptive statistics for physical activity-related outcomes by group at baseline and 10 weeks *,a.
| Experimental ( | Comparison ( | ||||
|---|---|---|---|---|---|
| Baseline | 10 Weeks | Baseline | 10 Weeks | ||
| Daily MVPA | 30.7 ± 13.2 | 34.2 ± 18.7 | 30.2 ± 16.2 | 37.8 ± 20.4 | 0.49 |
| Daily LPA | 91.4 ± 28.8 | 98.9 ± 29.5 | 100.4 ± 31.6 | 108.5 ± 47.9 | 0.76 |
| Daily SB | 464.4 ± 50.7 | 466.8 ± 34.7 | 449.2 ± 54.9 | 449.6 ± 53.2 | 0.82 |
| Daily EE | 333.1 ± 113.3 | 359.9 ± 147.4 | 395.5 ± 229.9 | 418.0 ± 188.9 | 0.44 |
| Daily steps | 4832.4 ± 1816.4 | 5175.1 ± 2308.2 | 4411.6 ± 1624.7 | 4746.0 ± 2044.9 | 0.76 |
* All values Mean ± Standard Deviation; a Per-protocol analysis presented; b p-value represents group difference in change from baseline to 10 weeks for a given outcome as assessed via Mann–Whitney U tests.
Descriptive statistics for physiological and psychosocial variables by group at baseline and 10 weeks *,a.
| Experimental ( | Comparison ( | ||||
|---|---|---|---|---|---|
| Baseline | 10 Weeks | Baseline | 10 Weeks | ||
| Physiological variables | |||||
| Weight (kg) | 76.6 ± 13.3 | 76.9 ± 12.2 | 78.0 ± 22.6 | 78.0 ± 23.0 | 0.62 |
| Body fat (%) | 39.8 ± 6.0 | 40.2 ± 5.4 | 36.0 ± 10.6 | 35.0 ± 10.8 | 0.12 |
| Cardiorespiratory fitness | 110.4 ± 18.5 | 105.7 ± 21.7 | 104.8 ± 29.3 | 100.3 ± 21.6 | 0.97 |
|
| |||||
| Self-efficacy # | 75.6 ± 25.1 | 67.9 ± 26.5 | 78.2 ± 12.1 | 71.8 ± 14.8 | 0.98 |
| Social support $ | 3.0 ± 1.1 | 2.7 ± 1.3 | 2.4 ± 1.1 | 3.0 ± 1.1 | 0.05 |
| Enjoyment $ | 3.3 ± 0.5 | 3.2 ± 0.5 | 3.2 ± 0.6 | 3.3 ± 0.6 | 0.53 |
| Barriers @ | 2.0 ± 0.5 | 2.0 ± 0.5 | 2.1 ± 0.2 | 1.8 ± 0.4 | 0.04 |
| Outcome expectancy $ | 4.1 ± 0.5 | 3.9 ± 0.5 | 4.0 ± 0.6 | 4.0 ± 0.6 | 0.34 |
* All values Mean ± Standard Deviation; a Per-protocol analysis presented; b p-value represents group difference in change from baseline to 10 weeks for a given outcome as assessed via independent t-tests; # Evaluated on a percentage confidence scale from 0% (Not confident at all) to 100% (Extremely confident); $ Evaluated on 5-point Likert-type scale; @ Evaluated on 4-point Likert-type scale.
Descriptive statistics for quality of life outcomes by group at baseline and 10 weeks *,a.
| Experimental ( | Comparison ( | ||||
|---|---|---|---|---|---|
| Baseline | 10 Weeks | Baseline | 10 Weeks | ||
| Physical functioning ** | 1.1 ± 0.2 | 1.1 ± 0.2 | 1.2 ± 0.2 | 1.1 ± 0.2 | 0.78 |
| Anxiety ** | 1.8 ± 0.8 | 2.0 ± 0.8 | 1.7 ± 0.7 | 1.5 ± 0.7 | 0.19 |
| Depression ** | 1.2 ± 0.3 | 1.4 ± 0.4 | 1.1 ± 0.3 | 1.1 ± 0.1 | 0.41 |
| Fatigue ** | 2.3 ± 1.0 | 2.3 ± 0.8 | 2.4 ± 0.6 | 2.2 ± 0.9 | 0.31 |
| Sleep quality ** | 3.1 ± 0.9 | 3.3 ± 0.6 | 3.6 ± 0.9 | 3.5 ± 0.9 | 0.62 |
| Sleep disturbances ** | 2.8 ± 0.6 | 2.5 ± 0.4 | 2.5 ± 0.5 | 2.5 ± 0.4 | 0.64 |
| Social roles/activities limitations ** | 2.0 ± 0.9 | 1.8 ± 0.7 | 1.9 ± 0.7 | 1.9 ± 0.5 | 0.64 |
| Pain limitations ** | 1.5 ± 0.5 | 1.5 ± 0.6 | 1.4 ± 0.5 | 1.4 ± 0.4 | 1.0 |
| Pain intensity & | 1.8 ± 1.0 | 1.8 ± 1.8 | 2.0 ± 1.9 | 1.8 ± 1.4 | 0.97 |
* All values Mean ± Standard Deviation; a Per-protocol analysis presented; b p-value represents group difference in change from baseline to 10 weeks for a given outcome as assessed via Mann–Whitney U tests; ** Evaluated on a 5-point Likert-type scale; & Evaluated on a scale from 0 (no pain) to 10 (worst pain imaginable).